keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/28641974/prostate-cancer-local-recurrence-detected-with-both-18-f-fluciclovine-and-psma-targeted-18-f-dcfpyl-pet-ct
#1
Michael A Gorin, Kenneth J Pienta, Martin G Pomper, Steven P Rowe
We present the case of a 79-year-old man with an elevated post-prostatectomy PSA level who was sequentially imaged with PET/CT using (18)F-fluciclovine followed by PSMA-targeted (18)F-DCFPyL. Although both imaging tests successfully identified the same pelvic recurrence, each radiotracer had its relative merits. This case highlights the differences between these two PET radiotracers which are increasingly being used to image men with recurrent prostate cancer.
June 19, 2017: Urology
https://www.readbyqxmd.com/read/28639122/targeting-prostate-specific-membrane-antigen-psma-with-f-18-labeled-compounds-the-influence-of-prosthetic-groups-on-tumor-uptake-and-clearance-profile
#2
Vincent Bouvet, Melinda Wuest, Justin J Bailey, Cody Bergman, Nancy Janzen, John F Valliant, Frank Wuest
PURPOSE: Prostate-specific membrane antigen (PSMA) is an important biomarker expressed in the majority of prostate cancers. The favorable positron emission tomography (PET) imaging profile of the PSMA imaging agent 2-(3-(1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentane-dioic acid [(18)F]DCFPyL in preclinical prostate cancer models and in prostate cancer patients stimulated the development and validation of other fluorine-containing PSMA inhibitors to further enhance pharmacokinetics and simplify production methods...
June 21, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28638485/psma-pet-for-lymph-node-detection-in-recurrent-prostate-cancer-how-do-we-use-the-magic-bullet
#3
EDITORIAL
Tobias Maurer, Declan G Murphy, Michael S Hofman, Matthias Eiber
No abstract text is available yet for this article.
2017: Theranostics
https://www.readbyqxmd.com/read/28637801/accuracy-in-the-eye-of-the-beholder-can-we-improve-agreement-in-prostate-cancer-diagnostics-with-psma-pet-ct
#4
Michael S Hofman
No abstract text is available yet for this article.
June 21, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28637799/-68-ga-psma-pet-ct-and-volumetric-morphology-of-pet-positive-lymph-nodes-stratified-by-tumor-differentiation-of-prostate-cancer
#5
Maria Vinsensia, Peter L Choyke, Boris Hadaschik, Tim Holland-Letz, Jan Moltz, Klaus Kopka, Isabel Rauscher, Walter Mier, Markus Schwaiger, Uwe Haberkorn, Tobias Maurer, Clemens Kratochwil, Matthias Eiber, Frederik Giesel
(68)Ga prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computer tomography (CT) is a new method to detect early nodal metastases in patients with biochemical relapse of prostate cancer (PCa). In this retrospective investigation the dimensions, volume, localization and maximum standardized uptake value (SUVmax) of nodes identified by (68)Ga-PSMA were correlated to their Gleason score (GS) at diagnosis. Methods: All PET/CT images were acquired 60±10 min after intravenous injection of (68)Ga-PSMA (mean dose 176 MBq)...
June 21, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28635336/new-advances-in-focal-therapy-for-early-stage-prostate-cancer
#6
Kae Jack Tay, Ariel A Schulman, Christina Sze, Efrat Tsivian, Thomas J Polascik
Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function. The prerequisites for successful focal therapy are to accurately identify, localize and completely ablate the clinically significant cancer(s) within the prostate. We aim to evaluate the evidence for current and upcoming technologies that could shape the future of prostate cancer focal therapy in the next five years. Areas Covered: Current literature on advances in patient selection using imaging, biopsy and biomarkers, ablation techniques and adjuvant treatments for focal therapy are summarized...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28632693/extraosseous-extension-of-aggressive-vertebral-hemangioma-as-a-potential-pitfall-on-68ga-psma-pet-ct
#7
Stephan Probst, Franck Bladou, Gad Abikhzer
A 74-year-old man with newly diagnosed prostate cancer underwent Ga-PSMA PET/CT, which demonstrated intense uptake in and adjacent the L2 vertebral body. Subsequent MRI of the lumbar spine showed an aggressive L2 hemangioma with adjacent soft tissue extension. There was congruence of the intraosseous and extraosseous components of the hemangioma and the PSMA PET uptake. This is a rare but important potential pitfall in Ga-PSMA PET/CT-a soft tissue lesion with intense tracer uptake related not to a nodal metastasis of prostate cancer but to extraosseous extension of an aggressive vertebral body hemangioma...
June 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28624849/the-accuracy-of-68-ga-psma-pet-ct-in-primary-lymph-node-staging-in-high-risk-prostate-cancer
#8
Can Öbek, Tünkut Doğanca, Emre Demirci, Meltem Ocak, Ali Rıza Kural, Asıf Yıldırım, Uğur Yücetaş, Çetin Demirdağ, Sarper M Erdoğan, Levent Kabasakal
PURPOSE: To assess the diagnostic accuracy of (68)Ga-PSMA PET in predicting lymph node (LN) metastases in primary N staging in high-risk and very high-risk nonmetastatic prostate cancer in comparison with morphological imaging. METHODS: This was a multicentre trial of the Society of Urologic Oncology in Turkey in conjunction with the Nuclear Medicine Department of Cerrahpasa School of Medicine, Istanbul University. Patients were accrued from eight centres. Patients with high-risk and very high-risk disease scheduled to undergo surgical treatment with extended LN dissection between July 2014 and October 2015 were included...
June 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28623872/uptake-in-sympathetic-ganglia-on-68-ga-psma-hbed-pet-ct-a-potential-pitfall-in-scan-interpretation
#9
Gowri L Kanthan, Edward Hsiao, Dzung Vu, Geoffrey Paul Schembri
INTRODUCTION: The aim of this study was to assess the frequency of PSMA-HBED uptake in coeliac and stellate ganglia in patients presenting for PSMA-HBED PET/CT scan. METHODS: Prostate-specific membrane antigen-HBED PET/CT scans of 100 consecutive patients were analysed. Coeliac and stellate ganglia were identified by their anatomical location. PSMA-HBED uptake in these ganglia was recorded as either present or absent. If present, the SUVmax value for each ganglion was measured and compared to SUVmax of mediastinal blood pool...
June 17, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28623852/frusemide-aids-diagnostic-interpretation-of-68-ga-psma-positron-emission-tomography-ct-in-men-with-prostate-cancer
#10
Niall Fennessy, Jonathan Lee, Jane Shin, Bao Ho, Syed Aman Ali, Royce Paschkewitz, Louise Emmett
INTRODUCTION: (68) Ga-PSMA positron emission tomography-computed tomography (PET/CT) is useful for both staging and assessment of biochemical relapse in men with prostate cancer. Renal excretion of (68) Ga-PSMA can lead to difficulties in scan interpretation, particularly in the pelvis. We evaluated if intravenous Frusemide at the time of (68) Ga-PSMA injection reduces excreted activity artefact and improves diagnostic certainty. METHODS: Sixty-two men with prostate cancer undergoing clinically indicated (68) Ga-PSMA PET/CT were prospectively included, 30 men receiving Frusemide at the time of radiotracer injection...
June 17, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/28619734/-68-ga-psma11-pet-ct-in-newly-diagnosed-carcinoma-of-the-prostate-correlation-of-intraprostatic-psma-uptake-with-several-clinical-parameters
#11
Stefan A Koerber, Maximilian T Utzinger, Clemens Kratochwil, Claudia Kesch, Matthias Haefner, Sonja Katayama, Walter Mier, Andrei H Iagaru, Klaus Herfarth, Uwe Haberkorn, Juergen Debus, Frederik L Giesel
(68)Ga-prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/ computer tomography (CT) is a promising diagnostic tool for patients with prostate cancer. Our study evaluates standardized uptake values (SUV) in benign prostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinical parameters. Methods: One hundred and four men with newly diagnosed prostate carcinoma and no previous therapy were included in this study. Maximum SUV (SUVmax) was measured and correlated with biopsy findings and magnetic resonance imaging (MRI)...
June 15, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28618401/64cu-psma-617-a-novel-psma-targeted-radio-tracer-for-pet-imaging-in-gastric-adenocarcinoma-xenografted-mice-model
#12
Xue-di Han, Chen Liu, Fei Liu, Qing-Hua Xie, Te-Li Liu, Xiao-Yi Guo, Xiao-Xia Xu, Xing Yang, Hua Zhu, Zhi Yang
Here, we report that it's feasible for imaging gastric adenocarcinoma mice model with prostate-specific membrane antigen (PSMA) targeting imaging agents, which could potentially provide an alternate and readily translational tool for managing gastric adenocarcinoma. DKFZ-PSMA-617, a PSMA targeting ligand reported recently, was chosen to be radio-labeled with nuclide 64Cu. 64Cu-PSMA-617 was radio-synthesized in high radio-chemical yield and specific activity up to 19.3 GBq/μmol. It showed good stability in vitro...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28613200/clinical-significance-of-18-f-fluorodeoxyglucose-avid-prostate-gland-incidentalomas-on-positron-emission-tomography-computed-tomography
#13
William Makis, Anthony Ciarallo
OBJECTIVE: The aim of this study was to evaluate the clinical significance of incidental focal uptake of (18)F-fluorodeoxyglucose ((18)F-FDG) on positron emission tomography/computed tomography (PET/CT) in the prostate glands of cancer patients. METHODS: A retrospective review of 3122 consecutive male patients who underwent (18)F-FDG PET/CT studies with an oncologic indication, over the course of four years, was performed. Studies with incidental (18)F-FDG uptake in the prostate gland were further analyzed...
June 1, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28612542/-establishment-of-bone-metastasis-model-of-prostate-cancer-in-mice-with-monitoring-of-18-f-naf-pet-ct
#14
Qiang You, Hua-Wei Cai, Fu-Wen Pang, Zhe-Tao Wang, Yue Chen, Rong Tian, Lin Li, Li-Hong Chen
OBJECTIVES: To establish a mouse model bearing human prostate cancer xenograft with bone metastasis by the monitoring with X-Ray, Micro CT, and ¹⁸F-NaF PET/CT. METHODS: Sixteen male Balb/c nude mice were allocated into control (6 mice) and experimental group (10 mice). In experimental group, the mice were subjected to percutaneous injection of 2×10(5)PC-3 cells into tibial plateau, bone defects were assessed after 21 d by X-ray, Micro-CT and ¹⁸F-NaF PET/CT, and bone damages were evaluated by HE staining...
March 2017: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://www.readbyqxmd.com/read/28612079/the-potential-of-223-ra-and-18-f-fluoride-imaging-to-predict-bone-lesion-response-to-treatment-with-223-ra-dichloride-in-castration-resistant-prostate-cancer
#15
Iain Murray, Sarah J Chittenden, Ana M Denis-Bacelar, Cecilia Hindorf, Christopher C Parker, Sue Chua, Glenn D Flux
PURPOSE: The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of (223)Ra-dichloride, to assess the relationship between those doses and corresponding (18)F-fluoride uptake and to assess the potential of quantitative (18)F-fluoride imaging to predict response to treatment. METHODS: Five patients received two intravenous injections of (223)Ra-dichloride, 6 weeks apart, at 110 kBq/kg whole-body weight. The biodistribution of (223)Ra in metastatic lesions as a function of time after administration as well as associated lesion dosimetry were determined from serial (223)Ra scans...
June 13, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28608163/prostate-specific-membrane-antigen-pet-mri-validation-of-mr-textural-analysis-for-detection-of-transition-zone-prostate-cancer
#16
Anthony Bates, Kenneth Miles
OBJECTIVES: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through comparison with co-registered prostate-specific membrane antigen (PSMA) PET-MR. METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured T2-weighted, transaxial, prostatic TZ using texture analysis software that applies a spatial band-pass filter and quantifies texture through histogram analysis...
June 12, 2017: European Radiology
https://www.readbyqxmd.com/read/28607878/targeted-prostate-biopsy-using-68-gallium-psma-pet-ct-for-image-guidance
#17
Demetrios N Simopoulos, Shyam Natarajan, Tonye A Jones, Wolfgang P Fendler, Anthony E Sisk, Leonard S Marks
Prostate specific membrane antigen (PSMA) scanning is a sensitive method of prostate cancer detection. In a 71 y.o. man with a PSA of 49 (6%F), 4 negative MRI studies and 6 negative biopsies over an 8 year interval, a (68)Ga-PSMA PET/CT scan showed a PSMA-avid spot in the prostate. Using image fusion technology, the lesion was target-biopsied and Gleason 3 + 4 = 7 (cancer core length of 12 mm) was identified. This case may herald a new application for PSMA scanning and prostate cancer imaging.
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28593386/prostate-specific-membrane-antigen-pet-imaging-and-immunohistochemistry-in-adenoid-cystic-carcinoma-%C3%AF-a-preliminary-analysis
#18
Thomas J W Klein Nulent, Robert J J van Es, Gerard C Krijger, Remco de Bree, Stefan M Willems, Bart de Keizer
BACKGROUND: Adenoid cystic carcinoma (AdCC) of the head and neck is an uncommon malignant epithelial tumour of the secretory glands. Many patients develop slowly growing local recurrence and/or distant metastasis, for which treatment options are limited. A retrospective analysis of 9 AdCC patients was conducted to analyse the visualization of AdCC on PSMA PET/CT and to investigate the expression of PSMA on primary, recurrent and metastatic AdCC tumour tissue using immunohistochemistry...
June 7, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28592703/real-time-transferrin-based-pet%C3%A2-detects-myc-positive-prostate-cancer
#19
Rahul Aggarwal, Spencer Behr, Pamela L Paris, Charles Truillet, Matthew F L Parker, Loc T Huynh, Junnian Wei, Byron Hann, Jack Youngren, Gayatri Premasekharan, Jiaoti Huang, Nimna Ranatunga, Emily Chang, Kenneth T Gao, Charles J Ryan, Eric J Small, Michael J Evans
Non-invasive biomarkers that detect the activity of important oncogenic drivers could significantly improve cancer diagnosis and management of treatment. The goal of this study was to determine if 68Ga-citrate (which avidly binds to circulating transferrin) labeled transferrin (Tf) can detect MYC-positive prostate cancer tumors, since the transferrin receptor is a direct MYC target gene. Positron emission tomography (PET) imaging paired with 68Ga-citrate and molecular analysis of preclinical models, human cell-free DNA (cfDNA) and clinical biopsies were conducted to determine whether 68Ga-citrate can detect MYC-positive prostate cancer...
June 7, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28590314/novel-imaging-in-advanced-prostate-cancer
#20
Hanan Goldberg, Robert J Hamilton
PURPOSE OF REVIEW: Prostate cancer (PCa) is the most commonly diagnosed noncutaneous cancer and second leading cause of death in men. Imaging evaluation of PCa is challenging because of the prostate's deep pelvic location, its complex zonal anatomy and its multifocal nature. Novel imaging modalities are needed to improve detection, reassessment in biochemical relapse, and disease progression in advanced metastatic stages. RECENT FINDINGS: Current imaging modalities have distinct strengths...
June 3, 2017: Current Opinion in Supportive and Palliative Care
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"